Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from the Children's Cancer Group
- 1 December 1996
- journal article
- clinical trial
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 27 (6) , 505-514
- https://doi.org/10.1002/(sici)1096-911x(199612)27:6<505::aid-mpo1>3.0.co;2-p
Abstract
The outcome of children with acute lymphoblastic leukemia (ALL) and bone marrow relapse has been unsatisfactory largely because of failure to prevent subsequent leukemia relapses. Ninety-six patients were enrolled and received vincristine, prednisone, L-asparaginase, and an anthracycline as reinduction therapy. Ninety-two patients were randomized to receive either daunomycin (DNR) or idarubicin (IDR). After achievement of second complete remission (CR2), maintenance chemotherapy included the same anthracycline, IDR or DNR, high-dose cytarabine, and escalating-dose methotrexate. Compared to DNR (45 mg/m2/week x 3), IDR (12.5 mg/m2/week x 3) was associated with prolonged myelosuppression and more frequent serious infections. Halfway through the study, the dose of IDR was reduced to 10 mg/m2. Overall, second remission was achieved in 71% of patients. Reinduction rate was similar for IDR and DNR. Reasons for induction failure differed; none of 15, 1 of 5, and 5 of 7 reinduction failures were due to infection for DNR, IDR (10 mg/m2), and IDR (12.5 mg/m2), respectively. Two-year event-free survival (EFS) was better among patients who received IDR (12.5 mg/m2) (27 +/- 18%) compared to DNR (10 +/- 8%, P = 0.05) and IDR (10 mg/m2) (6 +/- 12%, P = 0.02). However, after 3 years of follow-up, late events in the high-dose IDR group result in a similar EFS to the lower-dose IDR and DNR groups. In conclusion, IDR is an effective agent in childhood ALL. When used weekly at 12.5 mg/m2 during induction, the EFS outcome during the first 2 years of treatment appears better than lower-dose IDR or DNR (45 mg/m2), although this difference was not sustained at longer periods of follow-up. Increased hematopoietic toxicity seen at this dose might be reduced through the use of supportive measures, such as hematopoietins and intestinal decontamination.Keywords
This publication has 35 references indexed in Scilit:
- Bone marrow transplantation in childrenThe Journal of Pediatrics, 1993
- A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.Journal of Clinical Oncology, 1992
- Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: A report from the childrens cancer study groupMedical and Pediatric Oncology, 1992
- WHICH TREATMENT FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA IN SECOND REMISSION?The Lancet, 1987
- Intensive Retreatment of Childhood Acute Lymphoblastic Leukemia in First Bone Marrow RelapseNew England Journal of Medicine, 1986
- BONE-MARROW TRANSPLANTATION HAS A LIMITED ROLE IN PROLONGING SECOND MARROW REMISSION IN CHILDHOOD LYMPHOBLASTIC LEUKAEMIAThe Lancet, 1986
- A Comparison of Marrow Transplantation with Chemotherapy for Children with Acute Lymphoblastic Leukemia in Second or Subsequent RemissionNew England Journal of Medicine, 1981
- Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemiaCancer, 1980
- Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycinCancer Chemotherapy and Pharmacology, 1978
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977